tiprankstipranks
Trending News
More News >
Bio-Techne (TECH)
:TECH

Bio-Techne (TECH) AI Stock Analysis

Compare
499 Followers

Top Page

TE

Bio-Techne

(NASDAQ:TECH)

Rating:75Outperform
Price Target:
$58.00
▲(12.73%Upside)
Bio-Techne's strong financial performance and strategic earnings call guidance are major positive factors. However, high valuation concerns and technical analysis indicating potential longer-term challenges offset these strengths. Corporate events add a positive impact through shareholder value strategies.
Positive Factors
Financial Performance
Bio-Techne reported better-than-expected financial results for their 3Q25, including revenues of $316.2 million, an increase of 4.2% year-over-year, and increased adjusted earnings of $0.56 as compared to $0.48 one year ago.
Investment Opportunity
The recent pullback in TECH's share price offers a compelling entry point as it trades below its historical average, indicating an attractive investment opportunity.
Negative Factors
Market Exposure
TECH has exposure to US ACA/government end-market, which has weighed heavily on the stock.
Tariffs Impact
Company management was somewhat cautious in providing forward guidance for 4Q25E, due to uncertainties related to US government spending on R&D programs and the impact of tariffs on China and other international markets.

Bio-Techne (TECH) vs. SPDR S&P 500 ETF (SPY)

Bio-Techne Business Overview & Revenue Model

Company DescriptionBio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
How the Company Makes MoneyBio-Techne makes money primarily through the sale of its diverse range of biotechnology products and solutions. Key revenue streams include sales of proteins and antibodies, which are essential components for research and development in life sciences. The company also generates significant income from its immunoassay and diagnostic products, which are widely used in clinical settings to detect and quantify biological markers. Additionally, Bio-Techne benefits from partnerships and collaborations with academic institutions, research organizations, and pharmaceutical companies, enhancing its market reach and contributing to its earnings.

Bio-Techne Earnings Call Summary

Earnings Call Date:May 07, 2025
(Q3-2025)
|
% Change Since: 8.00%|
Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment Neutral
Bio-Techne reported strong organic revenue growth and a solid financial position with significant achievements in the pharma and diagnostics segments. However, challenges such as NIH funding uncertainty, tariff impacts, and difficulties in the China market present notable headwinds. The company's strategies to mitigate these challenges are promising, yet the timing and full impact remain uncertain.
Q3-2025 Updates
Positive Updates
Strong Organic Revenue Growth
Bio-Techne reported 6% organic revenue growth in a challenging macro environment, with a focus on profitability leading to an adjusted operating margin of 34.9%.
Pharma Segment Performance
The pharma segment showed low double-digit growth, driven by improved R&D pipelines and strong demand in the Protein Sciences segment with 7% organic revenue growth.
Protein Analytical Instrument Growth
The protein analytical instrumentation business, particularly the biologics platform Maurice, experienced double-digit growth driven by strong demand from pharma and CRO partners.
Diagnostics Growth
Year-to-date growth in diagnostic reagents was in the high-single digits, and the Asuragen portfolio saw low double-digit growth. The ExoDx prostate cancer test increased over 30% for the fiscal year-to-date.
Tariff Mitigation Strategies
Despite tariff challenges, Bio-Techne is well-positioned to mitigate impacts through optimization of global production and supply chain strategies, with expected full mitigation by the start of fiscal 2026.
Strong Financial Position
Bio-Techne reported $41.1 million in cash generated from operations, returned $12.6 million in dividends, and executed $100 million in stock buybacks. The company maintains a strong balance sheet with a total leverage ratio well below one time EBITDA.
Negative Updates
NIH Funding Uncertainty
US academic customers face uncertainty due to potential NIH funding cuts, impacting purchasing decisions, particularly around capital equipment.
Academic Market Challenges
The Spatial Biology segment, heavily exposed to US academic end markets, has been impacted by NIH funding uncertainty, affecting growth rates.
Tariff Challenges
Recent increases in global tariffs present a potential $20 million annual impact to adjusted operating income, with significant exposure from Chinese tariffs on proteomic analytical instruments.
China Market Decline
Revenue from China decreased mid-single digits due to ongoing economic challenges, contrasting with improved conditions in the rest of Asia.
Stalled Biotech Momentum
Momentum in the biotech sector has stalled due to global economic uncertainties, impacting growth expectations.
Company Guidance
During the third quarter of Fiscal Year 2025, Bio-Techne reported strong financial performance, with a 6% organic revenue growth and a 34.9% adjusted operating margin, despite a challenging macroeconomic environment. The company's growth was driven by low double-digit growth in the pharma sector, a 7% increase in the Protein Sciences segment, and a 2% growth in Diagnostics and Spatial Biology. The company also saw significant contributions from its GMP reagents, which grew at a high-single-digit rate, and its protein analytical instrumentation business. Bio-Techne's adjusted EPS rose to $0.56 from $0.48 in the previous year, with a GAAP EPS of $0.14. The company is strategically navigating challenges such as NIH funding uncertainties and tariff impacts, expecting full mitigation of tariff costs by the start of Fiscal Year 2026. Despite these challenges, Bio-Techne remains well-positioned for future growth, bolstered by its comprehensive product portfolio and strategic investments.

Bio-Techne Financial Statement Overview

Summary
Bio-Techne shows strong profitability with high gross profit margins and healthy net profit margins. The company maintains low leverage, reflecting financial stability. However, declining net income and free cash flow growth present minor challenges.
Income Statement
85
Very Positive
Bio-Techne exhibits strong profitability with a consistent Gross Profit Margin above 65% and a healthy Net Profit Margin around 10-12% over the years. The Revenue Growth Rate is notable, with a TTM growth of approximately 4.3% compared to the previous annual report. EBIT and EBITDA margins are robust, reflecting operational efficiency. However, a slight decline in net income in the TTM indicates potential challenges in managing costs or market pressures.
Balance Sheet
78
Positive
The company maintains a solid financial structure with a stable Debt-to-Equity Ratio of approximately 0.21, indicating low leverage. The Equity Ratio has strengthened to about 76.3%, showcasing healthy asset management. Return on Equity (ROE) is slightly decreasing, from 16.8% in 2023 to 6.5% in TTM, which may be a concern regarding profitability and asset utilization efficiency.
Cash Flow
80
Positive
Bio-Techne's cash flow position is strong, with positive Free Cash Flow and an Operating Cash Flow to Net Income Ratio of approximately 2.01 in TTM, indicating effective cash management. However, the Free Cash Flow Growth Rate is slightly negative, suggesting room for improvement in cash generation activities.
BreakdownTTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue1.21B1.16B1.14B1.11B931.03M738.69M
Gross Profit796.33M769.73M769.82M756.50M632.85M483.19M
EBITDA284.25M310.37M460.56M420.12M258.47M373.91M
Net Income131.67M168.10M285.26M272.05M140.41M229.30M
Balance Sheet
Total Assets2.64B2.70B2.64B2.29B2.26B2.03B
Cash, Cash Equivalents and Short-Term Investments140.67M152.86M204.31M247.03M231.55M270.89M
Total Debt423.50M419.54M454.96M325.97M420.55M433.53M
Total Liabilities626.23M635.02M672.18M593.79M691.72M646.40M
Stockholders Equity2.02B2.07B1.97B1.70B1.57B1.38B
Cash Flow
Free Cash Flow220.75M236.10M216.15M280.36M307.86M153.47M
Operating Cash Flow264.85M298.98M254.39M325.27M352.16M205.22M
Investing Cash Flow-44.40M-203.03M-265.65M-96.85M-243.52M27.09M
Financing Cash Flow-223.55M-122.40M22.62M-242.85M-62.55M-183.80M

Bio-Techne Technical Analysis

Technical Analysis Sentiment
Positive
Last Price51.45
Price Trends
50DMA
49.65
Positive
100DMA
55.28
Negative
200DMA
64.61
Negative
Market Momentum
MACD
0.48
Negative
RSI
54.17
Neutral
STOCH
72.40
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TECH, the sentiment is Positive. The current price of 51.45 is above the 20-day moving average (MA) of 50.38, above the 50-day MA of 49.65, and below the 200-day MA of 64.61, indicating a neutral trend. The MACD of 0.48 indicates Negative momentum. The RSI at 54.17 is Neutral, neither overbought nor oversold. The STOCH value of 72.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TECH.

Bio-Techne Risk Analysis

Bio-Techne disclosed 27 risk factors in its most recent earnings report. Bio-Techne reported the most risks in the "Production" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Bio-Techne Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
75
Outperform
$8.13B63.196.53%0.62%4.72%-35.33%
74
Outperform
$13.23B211.540.47%17.13%-88.78%
71
Outperform
$10.58B20.409.64%17.99%152.10%
71
Outperform
$4.01B33.4513.90%247.53%118.34%
65
Neutral
¥345.58B10.59-2.88%2.67%11.80%-6.84%
58
Neutral
$2.08B-31.51%
48
Neutral
$10.50B-29.34%-38.25%44.29%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TECH
Bio-Techne
51.45
-19.44
-27.42%
BMRN
BioMarin Pharmaceutical
54.97
-27.25
-33.14%
INCY
Incyte
68.10
9.08
15.38%
KRYS
Krystal Biotech
137.46
-40.15
-22.61%
MRNA
Moderna
27.59
-89.48
-76.43%
NAMS
NewAmsterdam Pharma Company
18.11
-2.19
-10.79%

Bio-Techne Corporate Events

Business Operations and StrategyFinancial Disclosures
Bio-Techne Reports Q3 2025 Financial Results
Neutral
May 7, 2025

On May 7, 2025, Bio-Techne Corporation announced its financial results for the third quarter of fiscal 2025, reporting a 6% increase in organic revenue to $316.2 million. The company saw a decline in GAAP earnings per share to $0.14 from $0.31 a year ago, but adjusted EPS rose to $0.56. The Protein Sciences segment experienced 7% organic growth, driven by improved pharma market conditions and strong commercial execution. The adjusted operating margin increased to 34.9%, reflecting profitability initiatives and volume leverage. Despite a challenging macroenvironment, Bio-Techne’s strategic positioning and leadership are expected to help navigate current conditions, enhancing its financial performance and market presence.

Stock Buyback
Bio-Techne Announces New $500M Share Repurchase Program
Positive
May 6, 2025

On April 30, 2025, Bio-Techne Corporation’s Board of Directors authorized a new share repurchase program, allowing the company to buy back up to $500 million of its common stock. This program replaces the previous one from February 2022 and has no set time limit. The repurchases can be made through various methods, including open market and private transactions, and are subject to market conditions and the company’s financial performance. The initiative aims to manage stock dilution and optimize capital needs, with disclosures to be made in the company’s annual and quarterly reports.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 26, 2025